Form 4: Dogwood CFO Granted 150,000 Stock Options

Dogwood Therapeutics' Chief Financial Officer, Angela Walsh, was granted 150,000 stock options with an exercise price of $6.14, vesting over time.

Summary

• Angela Walsh, Chief Financial Officer of Dogwood Therapeutics, Inc. (DWTX), was granted 150,000 stock options.
• The stock options have an exercise price of $6.14 per share.
• The transaction date for this grant was December 4, 2025.
• The options vest one-third on December 4, 2026, and 1/24th monthly thereafter.
• The expiration date for these stock options is December 4, 2035.
• Following this transaction, Angela Walsh beneficially owns 150,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally a positive for executive retention and alignment of interests, but not a significant driver of immediate company sentiment or financial performance.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of the shareholders, incentivizing long-term company performance.
• Stock options are a common form of executive compensation, indicating standard corporate practices for retaining and motivating key personnel.

Future Outlook

The vesting schedule for the stock options, extending through December 2026 and monthly thereafter, indicates an incentive for the Chief Financial Officer's continued tenure and performance with the company.

Industry Context

The grant of stock options to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries, as well as broader corporate sectors, to attract, retain, and motivate executive talent by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• Stock option grants are a widely accepted and common component of executive compensation packages across various industries, including biotechnology, aligning executive incentives with shareholder value creation.
• The vesting schedule, with an initial cliff vest followed by monthly vesting, is a typical structure designed to encourage long-term commitment and performance from executives.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with shareholders, potentially leading to better long-term performance, but also introduces potential future dilution upon exercise.
• Employees: May signal stability in executive leadership and standard compensation practices within the company.

Next Steps

• The stock options will begin vesting on December 4, 2026, with subsequent monthly vesting.

Key Dates

Keywords

Dogwood Therapeutics, DWTX, Angela Walsh, Chief Financial Officer, CFO, Stock Options, Executive Compensation, Insider Transaction, SEC Form 4, Equity Grant